Gliclazide: Independent Evidence on Hypos, Heart Safety & Funding

Table of contents

• Evidence summary
• What gliclazide is
• How it works
• What it is prescribed for
• What works and what does not
• Benefits by claim
• Risks and all side effects
• All interactions
• Who should avoid gliclazide
• Dosage and how to take it
• Follow the money: who makes it and who funded the evidence
• Related research
• Frequently asked questions
• Sources and funding notes

Evidence summary

Independent evidence and credibility scorecard

Independence tiers: 1 = regulator or government body; 2 = academic, Cochrane or professional-society team with no declared commercial funding for the work (or only donated supplies); 3 = independent authors with declared industry funding from a company with a stake in the result; 4 = manufacturer-funded or manufacturer-authored. Credibility runs from A (highest) to D.

Our sources cluster in the UK (four of twelve), with two from the US and one each from Italy, Denmark and Canada. The two manufacturer-funded trials pull in opposite directions: ADVANCE was part-funded by gliclazide's maker; CAROLINA by a competitor. Both, along with the publicly funded TOSCA.IT and GRADE trials, agree on the core picture: blood-sugar lowering, no clear cardiovascular harm or benefit, and more hypoglycaemia. That convergence between opposing interests is the strongest signal in this review.

What gliclazide is

Gliclazide is an oral sulfonylurea used for type 2 diabetes in adults "when dietary measures, physical exercise and weight loss alone are not sufficient" (SmPC). Its original brand is Diamicron, made by the French group Servier. It comes as standard 80 mg tablets, taken once or twice a day (Diamicron 80 mg SmPC), and as a modified-release (MR) 30 mg tablet, taken once a day at breakfast (Diamicron 30 mg MR SmPC). In the UK most prescriptions are now for unbranded generics.

The same class includes glimepiride (originally Amaryl, approved in the US in 1995 with Sanofi as the application holder; Drugs@FDA) and glipizide (Glucotrol, a Pfizer product first approved in the US in 1984; Drugs@FDA). Older sulfonylureas include glibenclamide (glyburide in the US), tolbutamide and chlorpropamide. We found no US approval record for gliclazide in the FDA's openFDA approvals database, so in the US glipizide and glimepiride fill its role.

Gliclazide is prescription-only in the UK. Prescribing in England has drifted down: from about 7.53 million items in 2015/16 to 5.85 million in 2025/26, a fall of about 22%, while dapagliflozin rose from 0.54 million to 11.6 million items over the same period (NHSBSA PCA, our query of the open data).

How it works

Gliclazide lowers blood glucose "by stimulating insulin secretion from the β-cells" of the pancreas (SmPC). Sulfonylureas act on the sulfonylurea receptor on these cells, which closes a potassium channel and triggers insulin release. A small Exeter crossover trial showed how much this depends on working beta-cells: people with a genetic form of diabetes (HNF-1α, a type of MODY) had a 3.9-fold greater response to gliclazide than people with type 2 diabetes (Pearson 2003).

This mechanism explains both the benefit and the main harm. Insulin is released whether or not you have eaten, so a missed meal, extra exercise or alcohol can push glucose too low. It also explains why the effect fades for many people: the SmPC notes that efficacy "is attenuated over time in many patients" as beta-cell function declines, which it calls secondary failure (SmPC).

Pharmacokinetics that matter in practice

Gliclazide is completely absorbed, about 95% bound to plasma proteins, and mainly broken down in the liver to inactive metabolites; less than 1% leaves unchanged in urine. Its half-life is 12–20 hours (SmPC). Because its metabolites are inactive, it is often preferred over glibenclamide in kidney impairment, though severe kidney failure remains a contraindication. The SmPC also claims "haemovascular properties" such as reduced platelet stickiness. These are laboratory and surrogate-marker findings from the maker's own product information; no outcome trial shows that they prevent heart attacks or strokes.

What it is prescribed for

Licensed uses

In the UK, gliclazide is licensed only for type 2 diabetes in adults, alone or combined with metformin, alpha-glucosidase inhibitors or insulin (SmPC). It is not for type 1 diabetes or diabetic ketoacidosis. Specialists also use sulfonylureas for some monogenic diabetes, based on trials such as the Exeter study above (Pearson 2003).

Where guidelines place it

NICE's February 2026 update changed first-line treatment to modified-release metformin with an SGLT-2 inhibitor for most adults (NICE NG28: initial medicines; update information). For people without other conditions who need more, NICE says to add a DPP-4 inhibitor first and, if that fails or is unsuitable, a sulfonylurea, pioglitazone or insulin (recommendation 1.25.1). For people with chronic kidney disease, a sulfonylurea is an option only if eGFR is 30 ml/min/1.73 m² or more (1.30.1). For people with frailty, NICE asks prescribers to "take into account" that sulfonylureas "can increase the risk of hypoglycaemia and falls" (1.31.2) (NICE NG28: further medication).

The American Geriatrics Society's 2023 Beers Criteria go further for older adults. They advise avoiding sulfonylureas as first- or second-line treatment "unless there are substantial barriers" to safer drugs, and preferring short-acting agents if one is used (strong recommendation; high-quality evidence for hypoglycaemia) (AGS Beers Criteria 2023).

What works and what does not

Benefits by claim

Blood sugar control

Lowering glucose is the one thing gliclazide clearly does. The best independent test is GRADE, run by the US National Institute of Diabetes and Digestive and Kidney Diseases. It randomised 5,047 people already on metformin, with diabetes for less than 10 years, to glimepiride, sitagliptin, liraglutide or insulin glargine, and followed them for an average of 5 years. All four drugs lowered HbA1c. Glargine and liraglutide were modestly better at keeping people on target; glimepiride sat in the middle, ahead of sitagliptin (GRADE glycaemic outcomes). In plain terms, a sulfonylurea is a respectable glucose-lowering drug, but it loses grip over time like the others.

Gliclazide itself was compared head to head with glimepiride in the 27-week GUIDE trial (n=845). HbA1c fell from 8.2–8.4% to 7.2% in both groups, and confirmed hypos below 3 mmol/L were less common with gliclazide MR (3.7% vs 8.9%) (Schernthaner 2004). GUIDE tested Servier's own MR tablet, and we could not access its funding statement, so we treat it as supportive but not independent.

Kidney and eye complications

Two famous trials are often quoted. The UK Prospective Diabetes Study (UKPDS 33) randomised 3,867 newly diagnosed people to intensive treatment with a sulfonylurea or insulin, or to diet. Over 10 years, intensive control cut microvascular endpoints by 25% (95% CI 7 to 40) but did not significantly reduce heart attacks or deaths during the trial (UKPDS 33). Its sulfonylureas were chlorpropamide, glibenclamide and glipizide, not gliclazide.

ADVANCE randomised 11,140 people to an intensive strategy built on gliclazide MR "plus other drugs as required" or to standard care. After 5 years, HbA1c was 6.5% vs 7.3%. The combined outcome fell by 10% (HR 0.90, 0.82 to 0.98), almost all from less new or worsening kidney disease (HR 0.79, 0.66 to 0.93). There was no significant effect on retinopathy, major cardiovascular events or death (Patel 2008). Servier was the major funder of the trial, alongside Australia's National Health and Medical Research Council (ACC summary; registry). The result shows that tighter glucose control helps the kidneys. It does not show that gliclazide has a special kidney effect, because the intensive arm also used more of other drugs.

Heart attacks, strokes and survival

No trial shows that gliclazide or any sulfonylurea helps people live longer. The Cochrane review of 72 trials (22,589 people) found no significant mortality difference between second-generation sulfonylureas and metformin (RR 0.98, 0.61 to 1.58) or other drugs, and judged none of the trials at low risk of bias across all domains (Hemmingsen 2013). The ADVANCE-ON post-trial follow-up (median 5.4 years for the glucose comparison) found no long-term effect of intensive glucose control on death (HR 1.00, 0.92 to 1.08) or major cardiovascular events (Zoungas 2014). By contrast, NICE now recommends SGLT-2 inhibitors and, in some groups, semaglutide specifically for cardiovascular and renal protection (NICE NG28).

Low cost

Cost is gliclazide's strongest practical advantage. In England in 2024/25, the net ingredient cost was about £2.67 per gliclazide item, against about £38 for dapagliflozin and £30 for linagliptin (our calculation from NHSBSA PCA 2024/25). Gliclazide accounted for 6.0 million items but only £16.0 million, while dapagliflozin's 8.75 million items cost £333 million.

Risks and all side effects

Hypoglycaemia

Hypoglycaemia is "the most frequent adverse reaction" listed in the SmPC. Symptoms range from hunger, sweating, tremor and palpitations to confusion, speech problems, fits, coma "and lethal outcome", and sweeteners do not treat it (SmPC). Risk factors include skipping or delaying meals, low-carbohydrate or low-calorie diets, strenuous exercise, alcohol, kidney or severe liver disease, thyroid, pituitary or adrenal problems, older age, and other glucose-lowering drugs.

How common is it? Trial figures vary with definitions and comparators:

• CAROLINA: at least one hypoglycaemic event in 37.7% on glimepiride vs 10.6% on linagliptin (HR 0.23); severe events needing another person's help in 2.2% vs 0.3% (CAROLINA).
• TOSCA.IT: hypos in 34% on sulfonylureas (mostly gliclazide or glimepiride) vs 10% on pioglitazone (Vaccaro 2017).
• GRADE: severe hypoglycaemia in 2.2% on glimepiride vs 1.3% glargine, 1.0% liraglutide and 0.7% sitagliptin (GRADE).
• ADVANCE: severe hypoglycaemia in 2.7% with gliclazide-based intensive control vs 1.5% with standard control (HR 1.86, 1.42 to 2.40) (ADVANCE).
• Pooled trials: hypos at or below 3.1 mmol/L in 10.1% of people on any sulfonylurea but 1.4% on gliclazide; severe hypos 0.8% overall and 0.1% on gliclazide (Schopman 2014). The authors caution that trial volunteers differ from everyday patients.

Real-world rates can be higher. In UK general-practice data, people who added or switched to a sulfonylurea had 5.5 severe hypos per 1,000 person-years vs 0.7 for those who stayed on metformin alone (HR 7.60, 4.64 to 12.44) (Douros 2018).

Weight gain

Because they raise insulin, sulfonylureas tend to add weight. In CAROLINA the glimepiride group gained 1.54 kg more than the linagliptin group (95% CI 1.28 to 1.80) (CAROLINA). In UKPDS, weight gain was 1.7 kg on glibenclamide and 2.6 kg on chlorpropamide, compared with 4.0 kg on insulin (UKPDS 33). In TOSCA.IT both sulfonylureas and pioglitazone caused moderate weight gain of under 2 kg on average (TOSCA.IT). In GRADE, average weight on glimepiride changed little over 4 years, while liraglutide users lost about 3.5 kg (GRADE full text).

Cardiovascular safety: the long-running debate

Concern dates back to the 1970s University Group Diabetes Program, in which tolbutamide was linked to about 2.5 times the cardiovascular death rate of diet alone. US labels for sulfonylureas, including glipizide, still carry a "potential increased risk of cardiovascular mortality" warning based on it (Glucotrol XL label).

Modern randomised trials are reassuring. CAROLINA, the only large double-blind cardiovascular outcome trial with a sulfonylurea comparator, found no difference between glimepiride and linagliptin (HR 0.98) (CAROLINA). TOSCA.IT found no difference vs pioglitazone (HR 0.96) (TOSCA.IT). GRADE found no differences in major cardiovascular events, heart-failure hospitalisation or death among its four drugs; for "any cardiovascular disease" glimepiride's hazard ratio vs the other three combined was 1.1 (0.9 to 1.4) (GRADE outcomes).

Observational data are less reassuring. In 77,138 UK metformin users, adding or switching to a sulfonylurea was linked to more heart attacks (HR 1.26, 1.01 to 1.56) and deaths (HR 1.28, 1.15 to 1.44) than staying on metformin alone, and switching looked worse than adding (Douros 2018). That study received funding from Boehringer Ingelheim, which sells rival drugs, as well as from Canadian public funders (BMJ full text). People who need a second drug may also be sicker than those who do not, which observational studies cannot fully adjust for. Among sulfonylureas, a network meta-analysis of 18 mostly observational studies found gliclazide linked to lower all-cause death than glibenclamide (RR 0.65, 0.53 to 0.79) (Simpson 2015).

Our reading: in trials, sulfonylureas look cardiovascular-neutral. They do not have the proven heart and kidney benefits of SGLT-2 inhibitors or some GLP-1 drugs.

Other side effects

• Digestive: abdominal pain, nausea, vomiting, indigestion, diarrhoea and constipation; taking the tablet with breakfast can reduce them (SmPC). The NHS lists stomach pain and diarrhoea as common (NHS).
• Skin: rash, itching, hives and angioedema; rarely severe blistering reactions (Stevens–Johnson syndrome, toxic epidermal necrolysis) and, exceptionally, DRESS.
• Blood: rarely anaemia, low white cells or platelets, usually reversible; haemolytic anaemia in G6PD deficiency.
• Liver: raised liver enzymes and isolated hepatitis; stop if cholestatic jaundice appears. Class reports include life-threatening liver failure in isolated cases.
• Other class effects: low sodium (hyponatraemia), allergic vasculitis, and transient blurred vision when glucose changes quickly. Acute porphyria has been described with other sulfonylureas.

All items above are from the UK product information (SmPC). The NHS lists allergic reactions, blood problems (easy bruising, sore throat, fever) and liver problems (yellow skin or eyes) as rare but serious (NHS).

Overdose

Overdose causes hypoglycaemia that can be severe, with coma or seizures. The SmPC describes hospital treatment with intravenous glucose and close monitoring, and notes that dialysis does not help because gliclazide is strongly protein-bound (SmPC).

All interactions

The UK product information groups interactions by effect (SmPC):

The NHS also flags weight-loss medicines such as semaglutide or tirzepatide, some antibiotics such as clarithromycin, and some heart and blood-pressure medicines (NHS). Any new medicine, herbal remedy or supplement should be checked with a pharmacist.

Who should avoid gliclazide

Contraindications

The SmPC says gliclazide must not be used with allergy to gliclazide, other sulfonylureas or sulfonamides; type 1 diabetes; diabetic pre-coma, coma or ketoacidosis; severe kidney or liver failure (where insulin is recommended); treatment with miconazole; or breastfeeding (SmPC).

Use with care

Extra caution applies to people with G6PD deficiency (risk of haemolytic anaemia; the SmPC suggests considering a non-sulfonylurea), porphyria, irregular meals or fasting, malnutrition, heavy exercise, thyroid, pituitary or adrenal disorders, severe vascular disease, and anyone stopping long-term high-dose steroids (SmPC). Fever, infection, trauma or surgery can upset glucose control; some people need insulin temporarily.

Older adults

Gliclazide's UK label uses the same dose in people over 65 (SmPC), but independent geriatric guidance is wary. The Beers Criteria rate the hypoglycaemia evidence as high quality and advise avoiding sulfonylureas unless safer agents are impractical (AGS Beers 2023). NICE asks prescribers to weigh hypoglycaemia and falls in people with frailty (NICE NG28). The FDA glipizide label likewise names older and kidney-impaired people as at-risk groups and suggests a lower starting dose (Glucotrol XL label).

Pregnancy and breastfeeding

The SmPC advises avoiding gliclazide in pregnancy and says insulin "is the drug of first choice"; it recommends switching before trying to conceive or as soon as pregnancy is known. It is contraindicated in breastfeeding because of the risk of low blood sugar in the baby (SmPC). The FDA glipizide label notes sulfonylureas cross the placenta and have been linked to prolonged low blood sugar in newborns (Glucotrol XL label).

Children and adolescents

The MR product information says safety and efficacy in children have not been established (SmPC), although the NHS page states that children aged 12 and over can take gliclazide (NHS). Use in young people is a specialist decision.

Kidney and liver disease

Mild to moderate kidney impairment does not change the label dose but needs careful monitoring; severe kidney or liver failure is a contraindication (SmPC). NICE limits sulfonylurea add-on in chronic kidney disease to eGFR of 30 or more and notes hypoglycaemia risk rises as kidney function falls (NICE NG28; initial medicines).

Dosage and how to take it

The figures below are label doses for information only. Your prescriber sets your dose.

Label doses

• Gliclazide MR 30 mg (Diamicron 30 mg MR): 30–120 mg once daily at breakfast, starting at 30 mg and increasing in steps usually at least a month apart; swallow whole; maximum 120 mg (SmPC). One 80 mg standard tablet is described as comparable to one 30 mg MR tablet.
• Standard gliclazide 80 mg: 40–320 mg a day, starting at 40–80 mg; no single dose above 160 mg, so higher totals are split across the two main meals (Diamicron 80 mg SmPC).
• Glipizide extended release (US): usually starting at 5 mg once daily (2.5 mg in older or liver-impaired people), maximum 20 mg once daily (Glucotrol XL label).
• Glimepiride: trials used 1–4 mg once daily (CAROLINA) or 2–6 mg (TOSCA.IT).

How to take it

Take it with a meal, usually breakfast, and do not skip meals. If a dose is missed, the label says not to increase the next day's dose (SmPC). The NHS advises not skipping or delaying meals and says it is best not to drink alcohol while taking gliclazide (NHS). People who fast for religious or medical reasons should plan doses with their clinician.

Driving

In the UK, the DVLA classes sulfonylureas as "tablets carrying hypoglycaemia risk". Car and motorcycle drivers need not notify the DVLA if they have adequate hypo awareness, have not had 2 or more severe hypos while awake in the last 12 months (with the latest more than 3 months ago), are under regular review and have no disqualifying complications; glucose checks at times relevant to driving are advised. Bus and lorry drivers must notify the DVLA and meet stricter rules, including no severe hypo in 12 months and glucose checks at least twice daily and at least every 2 hours while driving (DVLA, updated 7 November 2025). By contrast, metformin, DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 agonists are in a lower-risk category.

Stopping or switching

Gliclazide is not addictive and has no withdrawal syndrome, but stopping it without a replacement will usually let blood sugar rise. When switching from a long-acting sulfonylurea, the label notes a gap of a few days may be needed to avoid additive hypoglycaemia (SmPC). Changes should be made with the prescriber.

Follow the money: who makes it and who funded the evidence

Who made it, and who sells it now

Gliclazide's original brand, Diamicron, is authorised in the UK to Les Laboratoires Servier of Suresnes, France, and supplied by Servier Laboratories Ltd; the UK authorisation for Diamicron 80 mg dates from 21 December 1979 (30 mg MR SmPC; 80 mg SmPC). Servier describes itself as an independent group governed by a non-profit foundation, the Fondation Internationale de Recherche Servier (Servier governance). It reported group revenue of €6.9 billion in 2024/25, of which €1.55 billion came from generics; its results release did not break out diabetes or gliclazide sales (Servier 2024/25 results).

In England the brand now matters little. Of about 5.85 million gliclazide items in 2025/26, roughly 5,900 (about 0.1%) were listed under Servier; nearly all the rest were dispensed generically. The total net ingredient cost of gliclazide fell from £26.6 million in 2015/16 to £12.5 million in 2025/26 (our queries of NHSBSA PCA). Glimepiride's US originator is Sanofi (Drugs@FDA) and glipizide's is Pfizer (Drugs@FDA); both are widely available as generics.

So who profits either way? Because sulfonylureas are cheap generics, few companies gain much from promoting them. Makers of newer, patented drugs (SGLT-2 inhibitors, DPP-4 inhibitors, GLP-1 agonists) stand to gain if sulfonylureas are seen as unsafe. Health systems save money if sulfonylureas are seen as acceptable. Both pressures are worth keeping in mind.

Who funded the evidence

• ADVANCE: Servier was the major funder (it makes both gliclazide MR and the perindopril–indapamide pill tested in the same trial), with Australia's NHMRC; the trial was led by The George Institute (ACC summary; registry). The follow-up, ADVANCE-ON, lists the NHMRC "and others" (Zoungas 2014).
• CAROLINA: sponsored by Boehringer Ingelheim and Eli Lilly, which market linagliptin. The paper states Boehringer representatives were involved in the design and conduct of the study and that the sponsor contributed to data management, analysis and manuscript review, and several authors were Boehringer employees (CAROLINA full text).
• GRADE: US NIDDK grant, with donated medicines and supplies from Becton Dickinson, Bristol Myers Squibb, Merck, Novo Nordisk, Roche Diagnostics and Sanofi (GRADE full text).
• TOSCA.IT: Italian Medicines Agency, Diabete Ricerca and the Italian Diabetes Society (Vaccaro 2017).
• Douros 2018: Canadian public funders and Boehringer Ingelheim; Boehringer reviewed the manuscript but was not involved in design or conduct (BMJ full text).
• Simpson 2015: no funding declared (abstract).

Documented integrity event: the Mediator case

Servier's record includes a major legal case unrelated to gliclazide. On 20 December 2023 the Paris Court of Appeal convicted the Servier group over Mediator (benfluorex), a drug once marketed as a diabetes adjunct and widely used for weight loss, upholding convictions for aggravated deception and involuntary manslaughter and adding convictions for fraud and improperly obtaining marketing authorisations. The company reported fines of about €9 million and about €415 million in reimbursements to health insurers, called the decision "disputable and disappointing", and said it would appeal further (Servier statement). This does not tell us anything about gliclazide's safety, which rests on independent trials, but it is relevant context when weighing Servier-funded evidence.

Related research

For wider, evidence-graded context, see these Pure City Research guides:

• Type 2 diabetes: prevention and management evidence
• Diabetes and heart disease
• Diabetes supplements: benefits, limits and safety
• Berberine: glucose evidence and safety
• Chronic kidney disease and the heart
• Heart attack
• Stroke
• Heart disease in older adults
• Anticoagulants and bleeding safety
• Drug and supplement induced liver injury
• Alcohol and heart disease
• Porphyria

Frequently asked questions

Sources and funding notes

What we could not verify: the funding statements of the 2013 Cochrane review, the Schopman 2014 meta-analysis, the GUIDE trial, the Exeter MODY trial and UKPDS 33 (full texts were paywalled or blocked; we relied on abstracts and author affiliations). We could not open the NEJM ADVANCE paper and took its funding from the ACC trial summary and the ClinicalTrials.gov record. The UK product information gives 21 December 1979 as the first authorisation date for Diamicron 80 mg, but we could not confirm gliclazide's first worldwide marketing date or its patent history from a primary source, or find a US approval for gliclazide. Servier said in December 2023 that it would appeal the Mediator ruling to France's highest court; we could not confirm whether that appeal has been decided. Servier does not publish gliclazide sales separately. NHSBSA figures are our own queries of the open Prescription Cost Analysis data (community dispensing in England only; items, not patients). The NHS page and the SmPC differ on use in children aged 12 and over, and we could not resolve this.

1. Diamicron 30 mg MR Tablets: Summary of Product Characteristics (emc) — UK product information; marketing authorisation holder Les Laboratoires Servier (France), UK company Servier Laboratories Ltd.
2. Diamicron 80 mg Tablets: Summary of Product Characteristics (emc) — UK product information; Servier.
3. NICE NG28: Type 2 diabetes in adults, further medication (last updated 18 February 2026) — UK guideline; NICE (public body). Also initial medicines and update information.
4. DVLA: Diabetes mellitus, assessing fitness to drive (updated 7 November 2025) — UK government.
5. NHS: Gliclazide (reviewed 6 August 2026) — NHS England patient information.
6. NHSBSA Prescription Cost Analysis annual open data (2015/16 to 2025/26) — NHS Business Services Authority official statistics; our aggregation by chemical substance and supplier.
7. GRADE Research Group (Nathan DM et al.). Glycemia reduction in type 2 diabetes — glycemic outcomes. N Engl J Med 2022 — randomised trial; NIDDK with donated supplies (full text).
8. GRADE Research Group. Microvascular and cardiovascular outcomes. N Engl J Med 2022 — same trial; NIDDK and others.
9. Rosenstock J et al. CAROLINA: linagliptin vs glimepiride. JAMA 2019 — randomised trial; Boehringer Ingelheim and Eli Lilly (full text; NCT01243424).
10. Vaccaro O et al. TOSCA.IT: pioglitazone vs sulfonylureas. Lancet Diabetes Endocrinol 2017 — randomised trial; Italian Medicines Agency, Diabete Ricerca, Italian Diabetes Society.
11. ADVANCE Collaborative Group (Patel A et al.). Intensive blood glucose control and vascular outcomes. N Engl J Med 2008 — randomised trial; Servier and NHMRC (NCT00145925; ACC summary).
12. Zoungas S et al. ADVANCE-ON follow-up. N Engl J Med 2014 — post-trial follow-up; NHMRC and others.
13. Hemmingsen B et al. Sulphonylurea monotherapy for patients with type 2 diabetes. Cochrane Database Syst Rev 2013 — systematic review; Copenhagen Trial Unit; funding not accessed.
14. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin (UKPDS 33). Lancet 1998 — randomised trial; funding statement not accessed.
15. Douros A et al. Sulfonylureas as second line drugs. BMJ 2018 — UK cohort study; CIHR, Canadian Foundation for Innovation, Boehringer Ingelheim (full text).
16. Simpson SH et al. Mortality risk among sulfonylureas: network meta-analysis. Lancet Diabetes Endocrinol 2015 — meta-analysis; no funding.
17. Schopman JE et al. Incidence of hypoglycaemia with sulfonylureas. Diabetes Metab Res Rev 2014 — meta-analysis; Academic Medical Center Amsterdam; funding not accessed.
18. Schernthaner G et al. GUIDE study: gliclazide MR vs glimepiride. Eur J Clin Invest 2004 — randomised trial of Servier's MR tablet; funding statement not accessed.
19. Pearson ER et al. Genetic cause of hyperglycaemia and response to treatment. Lancet 2003 — crossover trial (n=36); funding not accessed.
20. American Geriatrics Society 2023 updated Beers Criteria. J Am Geriatr Soc 2023 — professional society guidance (full text).
21. Glucotrol XL (glipizide) prescribing information, DailyMed — FDA-approved label; Pfizer (Roerig).
22. Drugs@FDA: Amaryl (NDA 020496) and Glucotrol (NDA 017783) — US regulator records.
23. Servier: our governance model and 2024/25 results (27 January 2026) — company documents.
24. Servier statement on the Mediator Court of Appeal decision (20 December 2023) — company statement.

Educational research reviewed 7 October 2026. This article is not medical advice; talk to a qualified clinician or pharmacist before starting, stopping or combining treatments.